Literature DB >> 20694573

Repeated treatments with bevacizumab for recurrent radiation necrosis in patients with malignant brain tumors: a report of 2 cases.

Motomasa Furuse1, Shinji Kawabata, Toshihiko Kuroiwa, Shin-Ichi Miyatake.   

Abstract

Bevacizumab is expected to constitute a new treatment modality for radiation necrosis. In the present cases, we observed a recurrence of radiation necrosis after temporary improvement by bevacizumab treatment. Re-treatment with bevacizumab controlled the necrosis again. A 39-year-old male and a 57-year-old female were diagnosed with glioblastoma and lung cancer metastasis, respectively. The former patient underwent partial resection of the glioblastoma, followed by boron neutron capture therapy (BNCT) and 30 Gy of fractionated X-ray radiotherapy. Eleven months after BNCT, he suffered from left hemiparesis and convulsions with enlargement of a perifocal edema. The latter patient underwent stereotactic radiosurgery twice for the same tumor. Three months after the second radiosurgery, she had an uncontrollable convulsion and right hemiplegia with a massive perifocal edema. Both lesions were suggested to be radiation necroses by positron emission tomography using amino acids as a tracer. Neither patient responded to corticosteroids, anticoagulants, or vitamin E. They underwent treatment with 5 mg/kg bevacizumab biweekly, for a total of 6 cycles. The size of the perifocal edema was clearly reduced in response to the treatments. The neurological status of the patients improved concomitant with therapy. However, the clinical status of both patients was aggravated several months after the bevacizumab was stopped, and the perifocal edemas enlarged again. The patients underwent a second treatment with bevacizumab, and the perifocal edemas again decreased. Although radiation necrosis may recur several months after bevacizumab treatment, repeated bevacizumab treatments also appear to be effective.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20694573     DOI: 10.1007/s11060-010-0333-3

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  22 in total

1.  Striking regression of chronic radiotherapy damage in a clinical trial of combined pentoxifylline and tocopherol.

Authors:  S Delanian; S Balla-Mekias; J L Lefaix
Journal:  J Clin Oncol       Date:  1999-10       Impact factor: 44.544

Review 2.  Bevacizumab--current status and future directions.

Authors:  Rachel Midgley; David Kerr
Journal:  Ann Oncol       Date:  2005-06-06       Impact factor: 32.976

3.  Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.

Authors:  Kathy D Miller; Linnea I Chap; Frankie A Holmes; Melody A Cobleigh; P Kelly Marcom; Louis Fehrenbacher; Maura Dickler; Beth A Overmoyer; James D Reimann; Amy P Sing; Virginia Langmuir; Hope S Rugo
Journal:  J Clin Oncol       Date:  2005-02-01       Impact factor: 44.544

4.  Late effects of radiation on the central nervous system: role of vascular endothelial damage and glial stem cell survival.

Authors:  Jeffrey A Coderre; Gerard M Morris; Peggy L Micca; John W Hopewell; Ilja Verhagen; Bert J Kleiboer; Albert J van der Kogel
Journal:  Radiat Res       Date:  2006-09       Impact factor: 2.841

5.  Treatment of radiation-induced nervous system injury with heparin and warfarin.

Authors:  M J Glantz; P C Burger; A H Friedman; R A Radtke; E W Massey; S C Schold
Journal:  Neurology       Date:  1994-11       Impact factor: 9.910

6.  Evaluation of fluoride-labeled boronophenylalanine-PET imaging for the study of radiation effects in patients with glioblastomas.

Authors:  Minoru Miyashita; Shin-Ichi Miyatake; Yoshio Imahori; Kunio Yokoyama; Shinji Kawabata; Yoshinaga Kajimoto; Masa-Aki Shibata; Yoshinori Otsuki; Mitsunori Kirihata; Koji Ono; Toshihiko Kuroiwa
Journal:  J Neurooncol       Date:  2008-06-20       Impact factor: 4.130

7.  Diagnosis and treatment of progressive space-occupying radiation necrosis following stereotactic radiosurgery for brain metastasis: value of proton magnetic resonance spectroscopy.

Authors:  T Kimura; K Sako; Y Tohyama; S Aizawa; H Yoshida; T Aburano; K Tanaka; T Tanaka
Journal:  Acta Neurochir (Wien)       Date:  2003-07       Impact factor: 2.216

8.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

9.  Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.

Authors:  James J Vredenburgh; Annick Desjardins; James E Herndon; Jennifer Marcello; David A Reardon; Jennifer A Quinn; Jeremy N Rich; Sith Sathornsumetee; Sridharan Gururangan; John Sampson; Melissa Wagner; Leighann Bailey; Darell D Bigner; Allan H Friedman; Henry S Friedman
Journal:  J Clin Oncol       Date:  2007-10-20       Impact factor: 44.544

10.  Conservative treatment of delayed cerebral radiation necrosis.

Authors:  P J Shaw; D Bates
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-12       Impact factor: 10.154

View more
  39 in total

Review 1.  Treatment of pediatric cerebral radiation necrosis: a systematic review.

Authors:  N Drezner; K K Hardy; E Wells; G Vezina; C Y Ho; R J Packer; E I Hwang
Journal:  J Neurooncol       Date:  2016-07-20       Impact factor: 4.130

Review 2.  Super selective intra-arterial cerebral infusion of modern chemotherapeutics after blood-brain barrier disruption: where are we now, and where we are going.

Authors:  Randy S D'Amico; Deepak Khatri; Noah Reichman; Nitesh V Patel; Tamika Wong; Sherese R Fralin; Mona Li; Jason A Ellis; Rafael Ortiz; David J Langer; John A Boockvar
Journal:  J Neurooncol       Date:  2020-02-19       Impact factor: 4.130

3.  Can anti-vascular endothelial growth factor antibody reverse radiation necrosis? A preclinical investigation.

Authors:  Chong Duan; Carlos J Perez-Torres; Liya Yuan; John A Engelbach; Scott C Beeman; Christina I Tsien; Keith M Rich; Robert E Schmidt; Joseph J H Ackerman; Joel R Garbow
Journal:  J Neurooncol       Date:  2017-04-19       Impact factor: 4.130

Review 4.  Delayed brain radiation necrosis: pathological review and new molecular targets for treatment.

Authors:  Motomasa Furuse; Naosuke Nonoguchi; Shinji Kawabata; Shin-Ichi Miyatake; Toshihiko Kuroiwa
Journal:  Med Mol Morphol       Date:  2015-12       Impact factor: 2.309

5.  Low-dose bevacizumab as an effective pre-treatment for peri-tumoral brain edema prior to CyberKnife radiosurgery: A case report.

Authors:  Meng Xiangying; Zhao Rugang; Ding Lijuan; Zhao Yaowei; Sun Bing; Wang Junliang; Li Dan; Wu Shikai
Journal:  Cancer Biol Ther       Date:  2018-03-21       Impact factor: 4.742

Review 6.  Bevacizumab for radiation necrosis following treatment of high grade glioma: a systematic review of the literature.

Authors:  Daniel Lubelski; Kalil G Abdullah; Robert J Weil; Nicholas F Marko
Journal:  J Neurooncol       Date:  2013-09-05       Impact factor: 4.130

7.  The Effectiveness of Bevacizumab in Radionecrosis After Radiosurgery of a Single Brain Metastasis.

Authors:  Durim Delishaj; Stefano Ursino; Francesco Pasqualetti; Ilaria Pesaresi; Ilaria Desideri; Mirco Cosottini; Concetta Laliscia; Fabiola Paiar; Maria Grazia Fabrini
Journal:  Rare Tumors       Date:  2015-12-29

8.  Bevacizumab treatment leads to observable morphological and metabolic changes in brain radiation necrosis.

Authors:  Shingo Yonezawa; Kazuhiro Miwa; Jun Shinoda; Yuichi Nomura; Yoshitaka Asano; Noriyuki Nakayama; Naoyuki Ohe; Hirohito Yano; Toru Iwama
Journal:  J Neurooncol       Date:  2014-05-01       Impact factor: 4.130

9.  The distribution of vascular endothelial growth factor-producing cells in clinical radiation necrosis of the brain: pathological consideration of their potential roles.

Authors:  Naosuke Nonoguchi; Shin-Ichi Miyatake; Motoi Fukumoto; Motomasa Furuse; Ryo Hiramatsu; Shinji Kawabata; Toshihiko Kuroiwa; Motomu Tsuji; Manabu Fukumoto; Koji Ono
Journal:  J Neurooncol       Date:  2011-06-18       Impact factor: 4.130

10.  Salvage stereotactic radiosurgery with adjuvant use of bevacizumab for heavily treated recurrent brain metastases: a preliminary report.

Authors:  Shoji Yomo; Motohiro Hayashi
Journal:  J Neurooncol       Date:  2015-11-30       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.